APO Research
Talk to an analyst

APO RESEARCH · REPORT

Covid-19 Treatment

Patients today have more treatment options in the battle against coronavirus disease.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Patients today have more treatment options in the battle against coronavirus disease.

In November 2020, the FDA granted emergency use authorization to two monoclonal antibody treatments (bamlanivimab, made by Eli Lilly; and a combination of casirivimab and imdevimab, made by Regeneron). Both treatments have been approved for non-hospitalized adults and children over age 12 with mild to moderate COVID-19 symptoms who are at risk for developing severe COVID-19 or being hospitalized for it. In these patients, the approved treatments can reduce the risk of hospitalization and emergency room visits. These therapies must be given intravenously (by IV) soon after developing symptoms.

The FDA has approved the antiviral drug Veklury (remdesivir) for adults and certain pediatric patients with COVID-19 who are sick enough to need hospitalization. Veklury should only be administered in a hospital or in a health care setting capable of providing acute care comparable to inpatient hospital care.

The Drugs for Covid-19: Dexamethasone, Tocilizumab, Remdesivir, Baricitinib in combination with remdesivir, Anticoagulation drugs ("blood thinners"), etc.

In August 2020, the FDA issued an emergency use authorization (EUA) for convalescent plasma in patients hospitalized with COVID-19.

In this report, we study all treatment method for Covid-19.

Selected research

Market Analysis & Forecast

Global Covid-19 Treatment Market Analysis and Forecast 2026-2032

28 December 2025205 pages

Choose your research edition.

Industry ResearchCovid-19 Treatment Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Covid-19 Treatment Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Covid-19 Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Covid-19 Treatment Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Covid-19 Treatment Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

Patients today have more treatment options in the battle against coronavirus disease.

In November 2020, the FDA granted emergency use authorization to two monoclonal antibody treatments (bamlanivimab, made by Eli Lilly; and a combination of casirivimab and imdevimab, made by Regeneron). Both treatments have been approved for non-hospitalized adults and children over age 12 with mild to moderate COVID-19 symptoms who are at risk for developing severe COVID-19 or being hospitalized for it. In these patients, the approved treatments can reduce the risk of hospitalization and emergency room visits. These therapies must be given intravenously (by IV) soon after developing symptoms.

The FDA has approved the antiviral drug Veklury (remdesivir) for adults and certain pediatric patients with COVID-19 who are sick enough to need hospitalization. Veklury should only be administered in a hospital or in a health care setting capable of providing acute care comparable to inpatient hospital care.

Read the full market overview

The Drugs for Covid-19: Dexamethasone, Tocilizumab, Remdesivir, Baricitinib in combination with remdesivir, Anticoagulation drugs ("blood thinners"), etc.

In August 2020, the FDA issued an emergency use authorization (EUA) for convalescent plasma in patients hospitalized with COVID-19.

In this report, we study all treatment method for Covid-19.

Global core covid-19 treatment manufacturers include Cadila Healthcare, Novartis etc.The top 2 companies hold a share about 30%.North America is the largest market, with a share about 47%, followed by Europe and Asia Pacific with the share about 30% and 9%.

Report Includes

This report presents an overview of global market for Covid-19 Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Covid-19 Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Covid-19 Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Covid-19 Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Covid-19 Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Covid-19 Treatment revenue, projected growth trends, production technology, application and end-user industry.

Covid-19 Treatment Segment by Company

Cadila Healthcare

Johnson & Johnson

ImmunoPrecise

Novartis

AstraZeneca

Cipla

AbbVie

Bayer

Regeneron Pharmaceuticals

Ascletis Pharma

GlaxoSmithKline

Gilead Sciences

Pharmstandard

Fujifilm Holdings

Zhejiang Hisun Pharmaceutical Co. Ltd

Roche

Sanofi

Pfizer

Eli Lilly

Covid-19 Treatment Segment by Type

Life Support

Antiviral Medicine

Antibody Treatments

Others

Covid-19 Treatment Segment by End User

Children

Adult

Covid-19 Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Covid-19 Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Covid-19 Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Covid-19 Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Covid-19 Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Covid-19 Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Covid-19 Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Covid-19 Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Life Support Major Player Table 3. Antiviral Medicine Major Player Table 4. Antibody Treatments Major Player Table 5. Others Major Player Table 6. Global Covid-19 Treatment Market Size Growth Rate by End User (US$ Million), 2021 VS 2025 VS 2032 Table 7. Children Major Player Table 8. Adult Major Player Table 9. Covid-19 Treatment Industry Trends Table 10. Covid-19 Treatment Industry Drivers Table 11. Covid-19 Treatment Industry Opportunities and Challenges Table 12. Covid-19 Treatment Industry Restraints Table 13. Global Covid-19 Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Covid-19 Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Covid-19 Treatment Market Share by Region (2021-2026) Table 16. Global Covid-19 Treatment Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Covid-19 Treatment Market Share by Region (2027-2032) Table 18. Global Covid-19 Treatment Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Covid-19 Treatment Revenue Market Share by Players (2021-2026) Table 20. Global Covid-19 Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Covid-19 Treatment Key Players Headquarters & Area Served Table 22. Global Covid-19 Treatment Players, Product Type & Application Table 23. Global Covid-19 Treatment Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Covid-19 Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Covid-19 Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Covid-19 Treatment Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Covid-19 Treatment Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Covid-19 Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Covid-19 Treatment Revenue Market Share by Type (2027-2032) Table 31. Global Covid-19 Treatment Revenue by End User 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Covid-19 Treatment Revenue by End User (2021-2026) & (US$ Million) Table 33. Global Covid-19 Treatment Revenue by End User (2027-2032) & (US$ Million) Table 34. Global Covid-19 Treatment Revenue Market Share by End User (2021-2026) Table 35. Global Covid-19 Treatment Revenue Market Share by End User (2027-2032) Table 36. Cadila Healthcare Company Information Table 37. Cadila Healthcare Business Overview Table 38. Cadila Healthcare Covid-19 Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Cadila Healthcare Covid-19 Treatment Product Portfolio Table 40. Cadila Healthcare Recent Development Table 41. Johnson & Johnson Company Information Table 42. Johnson & Johnson Business Overview Table 43. Johnson & Johnson Covid-19 Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Johnson & Johnson Covid-19 Treatment Product Portfolio Table 45. Johnson & Johnson Recent Development Table 46. ImmunoPrecise Company Information Table 47. ImmunoPrecise Business Overview Table 48. ImmunoPrecise Covid-19 Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. ImmunoPrecise Covid-19 Treatment Product Portfolio Table 50. ImmunoPrecise Recent Development Table 51. Novartis Company Information Table 52. Novartis Business Overview Table 53. Novartis Covid-19 Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Novartis Covid-19 Treatment Product Portfolio Table 55. Novartis Recent Development Table 56. AstraZeneca Company Information Table 57. AstraZeneca Business Overview Table 58. AstraZeneca Covid-19 Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. AstraZeneca Covid-19 Treatment Product Portfolio Table 60. AstraZeneca Recent Development Table 61. Cipla Company Information Table 62. Cipla Business Overview Table 63. Cipla Covid-19 Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Cipla Covid-19 Treatment Product Portfolio Table 65. Cipla Recent Development Table 66. AbbVie Company Information Table 67. AbbVie Business Overview Table 68. AbbVie Covid-19 Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. AbbVie Covid-19 Treatment Product Portfolio Table 70. AbbVie Recent Development Table 71. Bayer Company Information Table 72. Bayer Business Overview Table 73. Bayer Covid-19 Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Bayer Covid-19 Treatment Product Portfolio Table 75. Bayer Recent Development Table 76. Regeneron Pharmaceuticals Company Information Table 77. Regeneron Pharmaceuticals Business Overview Table 78. Regeneron Pharmaceuticals Covid-19 Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Regeneron Pharmaceuticals Covid-19 Treatment Product Portfolio Table 80. Regeneron Pharmaceuticals Recent Development Table 81. Ascletis Pharma Company Information Table 82. Ascletis Pharma Business Overview Table 83. Ascletis Pharma Covid-19 Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Ascletis Pharma Covid-19 Treatment Product Portfolio Table 85. Ascletis Pharma Recent Development Table 86. GlaxoSmithKline Company Information Table 87. GlaxoSmithKline Business Overview Table 88. GlaxoSmithKline Covid-19 Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. GlaxoSmithKline Covid-19 Treatment Product Portfolio Table 90. GlaxoSmithKline Recent Development Table 91. Gilead Sciences Company Information Table 92. Gilead Sciences Business Overview Table 93. Gilead Sciences Covid-19 Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Gilead Sciences Covid-19 Treatment Product Portfolio Table 95. Gilead Sciences Recent Development Table 96. Pharmstandard Company Information Table 97. Pharmstandard Business Overview Table 98. Pharmstandard Covid-19 Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Pharmstandard Covid-19 Treatment Product Portfolio Table 100. Pharmstandard Recent Development Table 101. Fujifilm Holdings Company Information Table 102. Fujifilm Holdings Business Overview Table 103. Fujifilm Holdings Covid-19 Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Fujifilm Holdings Covid-19 Treatment Product Portfolio Table 105. Fujifilm Holdings Recent Development Table 106. Zhejiang Hisun Pharmaceutical Co. Ltd Company Information Table 107. Zhejiang Hisun Pharmaceutical Co. Ltd Business Overview Table 108. Zhejiang Hisun Pharmaceutical Co. Ltd Covid-19 Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Zhejiang Hisun Pharmaceutical Co. Ltd Covid-19 Treatment Product Portfolio Table 110. Zhejiang Hisun Pharmaceutical Co. Ltd Recent Development Table 111. Roche Company Information Table 112. Roche Business Overview Table 113. Roche Covid-19 Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Roche Covid-19 Treatment Product Portfolio Table 115. Roche Recent Development Table 116. Sanofi Company Information Table 117. Sanofi Business Overview Table 118. Sanofi Covid-19 Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Sanofi Covid-19 Treatment Product Portfolio Table 120. Sanofi Recent Development Table 121. Pfizer Company Information Table 122. Pfizer Business Overview Table 123. Pfizer Covid-19 Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Pfizer Covid-19 Treatment Product Portfolio Table 125. Pfizer Recent Development Table 126. Eli Lilly Company Information Table 127. Eli Lilly Business Overview Table 128. Eli Lilly Covid-19 Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Eli Lilly Covid-19 Treatment Product Portfolio Table 130. Eli Lilly Recent Development Table 131. North America Covid-19 Treatment Revenue by Type (2021-2026) & (US$ Million) Table 132. North America Covid-19 Treatment Revenue by Type (2027-2032) & (US$ Million) Table 133. North America Covid-19 Treatment Revenue by End User (2021-2026) & (US$ Million) Table 134. North America Covid-19 Treatment Revenue by End User (2027-2032) & (US$ Million) Table 135. North America Covid-19 Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. North America Covid-19 Treatment Revenue by Country (2021-2026) & (US$ Million) Table 137. North America Covid-19 Treatment Revenue by Country (US$ Million) & (2027-2032) Table 138. Europe Covid-19 Treatment Revenue by Type (2021-2026) & (US$ Million) Table 139. Europe Covid-19 Treatment Revenue by Type (2027-2032) & (US$ Million) Table 140. Europe Covid-19 Treatment Revenue by End User (2021-2026) & (US$ Million) Table 141. Europe Covid-19 Treatment Revenue by End User (2027-2032) & (US$ Million) Table 142. Europe Covid-19 Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Europe Covid-19 Treatment Revenue by Country (2021-2026) & (US$ Million) Table 144. Europe Covid-19 Treatment Revenue by Country (US$ Million) & (2027-2032) Table 145. China Covid-19 Treatment Revenue by Type (2021-2026) & (US$ Million) Table 146. China Covid-19 Treatment Revenue by Type (2027-2032) & (US$ Million) Table 147. China Covid-19 Treatment Revenue by End User (2021-2026) & (US$ Million) Table 148. China Covid-19 Treatment Revenue by End User (2027-2032) & (US$ Million) Table 149. Asia Covid-19 Treatment Revenue by Type (2021-2026) & (US$ Million) Table 150. Asia Covid-19 Treatment Revenue by Type (2027-2032) & (US$ Million) Table 151. Asia Covid-19 Treatment Revenue by End User (2021-2026) & (US$ Million) Table 152. Asia Covid-19 Treatment Revenue by End User (2027-2032) & (US$ Million) Table 153. Asia Covid-19 Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 154. Asia Covid-19 Treatment Revenue by Region (US$ Million) & (2021-2026) Table 155. Asia Covid-19 Treatment Revenue by Region (US$ Million) & (2027-2032) Table 156. SAMEA Covid-19 Treatment Revenue by Type (2021-2026) & (US$ Million) Table 157. SAMEA Covid-19 Treatment Revenue by Type (2027-2032) & (US$ Million) Table 158. SAMEA Covid-19 Treatment Revenue by End User (2021-2026) & (US$ Million) Table 159. SAMEA Covid-19 Treatment Revenue by End User (2027-2032) & (US$ Million) Table 160. SAMEA Covid-19 Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 161. SAMEA Covid-19 Treatment Revenue by Country (2021-2026) & (US$ Million) Table 162. SAMEA Covid-19 Treatment Revenue by Country (US$ Million) & (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Covid-19 Treatment Image Figure 2. Global Covid-19 Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Covid-19 Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Life Support Image Figure 5. Antiviral Medicine Image Figure 6. Antibody Treatments Image Figure 7. Others Image Figure 8. Global Covid-19 Treatment Market Size Growth Rate by End User (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Covid-19 Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Children Image Figure 11. Adult Image Figure 12. Global Covid-19 Treatment Market Size (US$ Million) & (2021-2032) Figure 13. Global Covid-19 Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Covid-19 Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Covid-19 Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Covid-19 Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Covid-19 Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Covid-19 Treatment Revenue Market Share by Type (2021-2032) Figure 20. Global Covid-19 Treatment Revenue by End User (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Covid-19 Treatment Revenue Market Share by End User (2021 VS 2025 VS 2032) Figure 22. Global Covid-19 Treatment Revenue Market Share by End User (2021-2032) Figure 23. North America Covid-19 Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Covid-19 Treatment Revenue Share by Type (2021-2032) Figure 25. North America Covid-19 Treatment Revenue Share by Application (2021-2032) Figure 26. North America Covid-19 Treatment Revenue Share by Country (2021-2032) Figure 27. United States Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Covid-19 Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Covid-19 Treatment Revenue Share by Type (2021-2032) Figure 32. Europe Covid-19 Treatment Revenue Share by Application (2021-2032) Figure 33. Europe Covid-19 Treatment Revenue Share by Country (2021-2032) Figure 34. Germany Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Covid-19 Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Covid-19 Treatment Revenue Share by Type (2021-2032) Figure 44. China Covid-19 Treatment Revenue Share by Application (2021-2032) Figure 45. Asia Covid-19 Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Covid-19 Treatment Revenue Share by Type (2021-2032) Figure 47. Asia Covid-19 Treatment Revenue Share by Application (2021-2032) Figure 48. Asia Covid-19 Treatment Revenue Share by Region (2021-2032) Figure 49. Japan Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Covid-19 Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Covid-19 Treatment Revenue Share by Type (2021-2032) Figure 57. SAMEA Covid-19 Treatment Revenue Share by Application (2021-2032) Figure 58. SAMEA Covid-19 Treatment Revenue Share by Country (2021-2032) Figure 59. Brazil Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Covid-19 Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Life Support
  • Antiviral Medicine
  • Antibody Treatments
  • Others
Applications
  • Children
  • Adult
Companies covered
  • Cadila Healthcare
  • Johnson & Johnson
  • ImmunoPrecise
  • Novartis
  • AstraZeneca
  • Cipla
  • AbbVie
  • Bayer
  • Regeneron Pharmaceuticals
  • Ascletis Pharma
  • GlaxoSmithKline
  • Gilead Sciences
  • Pharmstandard
  • Fujifilm Holdings
  • Zhejiang Hisun Pharmaceutical Co. Ltd
  • Roche
  • Sanofi
  • Pfizer
  • Eli Lilly

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Covid-19 Treatment Market by Type
  3. 1.2.1 Global Covid-19 Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Life Support
  5. 1.2.3 Antiviral Medicine
  6. 1.2.4 Antibody Treatments
  7. 1.2.5 Others
  8. 1.3 Covid-19 Treatment Market by End User
  9. 1.3.1 Global Covid-19 Treatment Market Size by End User, 2021 VS 2025 VS 2032
  10. 1.3.2 Children
  11. 1.3.3 Adult
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Covid-19 Treatment Market Dynamics
  1. 2.1 Covid-19 Treatment Industry Trends
  2. 2.2 Covid-19 Treatment Industry Drivers
  3. 2.3 Covid-19 Treatment Industry Opportunities and Challenges
  4. 2.4 Covid-19 Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Covid-19 Treatment Market Perspective (2021-2032)
  2. 3.2 Global Covid-19 Treatment Growth Trends by Region
  3. 3.2.1 Global Covid-19 Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Covid-19 Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Covid-19 Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Covid-19 Treatment Revenue by Players
  2. 4.1.1 Global Covid-19 Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Covid-19 Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Covid-19 Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Covid-19 Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Covid-19 Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Covid-19 Treatment Players, Product Type & Application
  8. 4.5 Global Covid-19 Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Covid-19 Treatment Market CR5 and HHI
  11. 4.6.3 2025 Covid-19 Treatment Tier 1, Tier 2, and Tier 3
5 Covid-19 Treatment Market Size by Type
  1. 5.1 Global Covid-19 Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Covid-19 Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Covid-19 Treatment Revenue Market Share by Type (2021-2032)
6 Covid-19 Treatment Market Size by Application
  1. 6.1 Global Covid-19 Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Covid-19 Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Covid-19 Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Cadila Healthcare
  2. 7.1.1 Cadila Healthcare Company Information
  3. 7.1.2 Cadila Healthcare Business Overview
  4. 7.1.3 Cadila Healthcare Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Cadila Healthcare Covid-19 Treatment Product Portfolio
  6. 7.1.5 Cadila Healthcare Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Covid-19 Treatment Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 ImmunoPrecise
  14. 7.3.1 ImmunoPrecise Company Information
  15. 7.3.2 ImmunoPrecise Business Overview
  16. 7.3.3 ImmunoPrecise Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 ImmunoPrecise Covid-19 Treatment Product Portfolio
  18. 7.3.5 ImmunoPrecise Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Covid-19 Treatment Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Covid-19 Treatment Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Cipla
  32. 7.6.1 Cipla Company Information
  33. 7.6.2 Cipla Business Overview
  34. 7.6.3 Cipla Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Cipla Covid-19 Treatment Product Portfolio
  36. 7.6.5 Cipla Recent Developments
  37. 7.7 AbbVie
  38. 7.7.1 AbbVie Company Information
  39. 7.7.2 AbbVie Business Overview
  40. 7.7.3 AbbVie Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AbbVie Covid-19 Treatment Product Portfolio
  42. 7.7.5 AbbVie Recent Developments
  43. 7.8 Bayer
  44. 7.8.1 Bayer Company Information
  45. 7.8.2 Bayer Business Overview
  46. 7.8.3 Bayer Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Bayer Covid-19 Treatment Product Portfolio
  48. 7.8.5 Bayer Recent Developments
  49. 7.9 Regeneron Pharmaceuticals
  50. 7.9.1 Regeneron Pharmaceuticals Company Information
  51. 7.9.2 Regeneron Pharmaceuticals Business Overview
  52. 7.9.3 Regeneron Pharmaceuticals Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Regeneron Pharmaceuticals Covid-19 Treatment Product Portfolio
  54. 7.9.5 Regeneron Pharmaceuticals Recent Developments
  55. 7.10 Ascletis Pharma
  56. 7.10.1 Ascletis Pharma Company Information
  57. 7.10.2 Ascletis Pharma Business Overview
  58. 7.10.3 Ascletis Pharma Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Ascletis Pharma Covid-19 Treatment Product Portfolio
  60. 7.10.5 Ascletis Pharma Recent Developments
  61. 7.11 GlaxoSmithKline
  62. 7.11.1 GlaxoSmithKline Company Information
  63. 7.11.2 GlaxoSmithKline Business Overview
  64. 7.11.3 GlaxoSmithKline Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 GlaxoSmithKline Covid-19 Treatment Product Portfolio
  66. 7.11.5 GlaxoSmithKline Recent Developments
  67. 7.12 Gilead Sciences
  68. 7.12.1 Gilead Sciences Company Information
  69. 7.12.2 Gilead Sciences Business Overview
  70. 7.12.3 Gilead Sciences Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Gilead Sciences Covid-19 Treatment Product Portfolio
  72. 7.12.5 Gilead Sciences Recent Developments
  73. 7.13 Pharmstandard
  74. 7.13.1 Pharmstandard Company Information
  75. 7.13.2 Pharmstandard Business Overview
  76. 7.13.3 Pharmstandard Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Pharmstandard Covid-19 Treatment Product Portfolio
  78. 7.13.5 Pharmstandard Recent Developments
  79. 7.14 Fujifilm Holdings
  80. 7.14.1 Fujifilm Holdings Company Information
  81. 7.14.2 Fujifilm Holdings Business Overview
  82. 7.14.3 Fujifilm Holdings Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Fujifilm Holdings Covid-19 Treatment Product Portfolio
  84. 7.14.5 Fujifilm Holdings Recent Developments
  85. 7.15 Zhejiang Hisun Pharmaceutical Co. Ltd
  86. 7.15.1 Zhejiang Hisun Pharmaceutical Co. Ltd Company Information
  87. 7.15.2 Zhejiang Hisun Pharmaceutical Co. Ltd Business Overview
  88. 7.15.3 Zhejiang Hisun Pharmaceutical Co. Ltd Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Zhejiang Hisun Pharmaceutical Co. Ltd Covid-19 Treatment Product Portfolio
  90. 7.15.5 Zhejiang Hisun Pharmaceutical Co. Ltd Recent Developments
  91. 7.16 Roche
  92. 7.16.1 Roche Company Information
  93. 7.16.2 Roche Business Overview
  94. 7.16.3 Roche Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Roche Covid-19 Treatment Product Portfolio
  96. 7.16.5 Roche Recent Developments
  97. 7.17 Sanofi
  98. 7.17.1 Sanofi Company Information
  99. 7.17.2 Sanofi Business Overview
  100. 7.17.3 Sanofi Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Sanofi Covid-19 Treatment Product Portfolio
  102. 7.17.5 Sanofi Recent Developments
  103. 7.18 Pfizer
  104. 7.18.1 Pfizer Company Information
  105. 7.18.2 Pfizer Business Overview
  106. 7.18.3 Pfizer Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Pfizer Covid-19 Treatment Product Portfolio
  108. 7.18.5 Pfizer Recent Developments
  109. 7.19 Eli Lilly
  110. 7.19.1 Eli Lilly Company Information
  111. 7.19.2 Eli Lilly Business Overview
  112. 7.19.3 Eli Lilly Covid-19 Treatment Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Eli Lilly Covid-19 Treatment Product Portfolio
  114. 7.19.5 Eli Lilly Recent Developments
8 North America
  1. 8.1 North America Covid-19 Treatment Revenue (2021-2032)
  2. 8.2 North America Covid-19 Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Covid-19 Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Covid-19 Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Covid-19 Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Covid-19 Treatment Revenue by End User (2021-2032)
  7. 8.4.1 North America Covid-19 Treatment Revenue by End User (2021-2026)
  8. 8.4.2 North America Covid-19 Treatment Revenue by End User (2027-2032)
  9. 8.5 North America Covid-19 Treatment Revenue Share by End User (2021-2032)
  10. 8.6 North America Covid-19 Treatment Revenue by Country
  11. 8.6.1 North America Covid-19 Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Covid-19 Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Covid-19 Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Covid-19 Treatment Revenue (2021-2032)
  2. 9.2 Europe Covid-19 Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Covid-19 Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Covid-19 Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Covid-19 Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Covid-19 Treatment Revenue by End User (2021-2032)
  7. 9.4.1 Europe Covid-19 Treatment Revenue by End User (2021-2026)
  8. 9.4.2 Europe Covid-19 Treatment Revenue by End User (2027-2032)
  9. 9.5 Europe Covid-19 Treatment Revenue Share by End User (2021-2032)
  10. 9.6 Europe Covid-19 Treatment Revenue by Country
  11. 9.6.1 Europe Covid-19 Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Covid-19 Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Covid-19 Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Covid-19 Treatment Revenue (2021-2032)
  2. 10.2 China Covid-19 Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Covid-19 Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Covid-19 Treatment Revenue by Type (2027-2032)
  5. 10.3 China Covid-19 Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Covid-19 Treatment Revenue by End User (2021-2032)
  7. 10.4.1 China Covid-19 Treatment Revenue by End User (2021-2026)
  8. 10.4.2 China Covid-19 Treatment Revenue by End User (2027-2032)
  9. 10.5 China Covid-19 Treatment Revenue Share by End User (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Covid-19 Treatment Revenue (2021-2032)
  2. 11.2 Asia Covid-19 Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Covid-19 Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Covid-19 Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Covid-19 Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Covid-19 Treatment Revenue by End User (2021-2032)
  7. 11.4.1 Asia Covid-19 Treatment Revenue by End User (2021-2026)
  8. 11.4.2 Asia Covid-19 Treatment Revenue by End User (2027-2032)
  9. 11.5 Asia Covid-19 Treatment Revenue Share by End User (2021-2032)
  10. 11.6 Asia Covid-19 Treatment Revenue by Country
  11. 11.6.1 Asia Covid-19 Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Covid-19 Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Covid-19 Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Covid-19 Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Covid-19 Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Covid-19 Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Covid-19 Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Covid-19 Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Covid-19 Treatment Revenue by End User (2021-2032)
  7. 12.4.1 SAMEA Covid-19 Treatment Revenue by End User (2021-2026)
  8. 12.4.2 SAMEA Covid-19 Treatment Revenue by End User (2027-2032)
  9. 12.5 SAMEA Covid-19 Treatment Revenue Share by End User (2021-2032)
  10. 12.6 SAMEA Covid-19 Treatment Revenue by Country
  11. 12.6.1 SAMEA Covid-19 Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Covid-19 Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Covid-19 Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst